Product Description
Degarelix injection is used to treat advanced prostate cancer (cancer that begins in the prostate [a male reproductive gland]). Degarelix injection is in a class of medications called gonadotropin-releasing hormone (GnRH) receptor antagonists. It works by decreasing the amount of testosterone (a male hormone) produced by the body. This may slow or stop the spread of prostate cancer cells that need testosterone to grow. (Sourced from: https://medlineplus.gov/druginfo/meds/a609022.html)
Mechanisms of Action: GnRH Antagonist
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Subcutaneous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Belgium | Bosnia | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Mexico | Netherlands | Norway | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Ferring
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Belgium, Canada, France, United States
Active Clinical Trial Count: 13
Highest Development Phases
Phase 3: Adenocarcinoma|Prostate Cancer
Phase 2: Male Breast Cancer
Phase 1: Bladder Cancer|Transitional Cell Carcinoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| PREDICT-RT* | P3 |
Recruiting |
Adenocarcinoma|Prostate Cancer |
2033-12-31 |
|
| S65935 | P3 |
Recruiting |
Prostate Cancer |
2032-06-01 |
|
| STAMPEDE | P3 |
Unknown status |
Prostate Cancer |
2030-12-04 |
|
| SChLAP/IDC | P2 |
Not yet recruiting |
Prostate Cancer |
2028-12-01 |
63% |
| MCC-21139 | P2 |
Active, not recruiting |
Prostate Cancer |
2027-07-15 |
12% |
| TASUC-Neo | P1 |
Recruiting |
Transitional Cell Carcinoma|Bladder Cancer |
2027-01-01 |
|
| GUIDANCE | P3 |
Recruiting |
Prostate Cancer|Adenocarcinoma |
2026-11-11 |
|
| CAAA802A12101 | P2 |
Recruiting |
Prostate Cancer |
2026-08-01 |
|
| ETHAN | P2 |
Recruiting |
Male Breast Cancer |
2026-04-01 |
12% |
| Neo-Red-P | P1 |
Active, not recruiting |
Prostate Cancer |
2025-06-01 |
4% |
| AFT-19 | P3 |
Active, not recruiting |
Prostate Cancer |
2025-07-01 |
28% |
| Pro00061532 | P2 |
Active, not recruiting |
Adenocarcinoma|Prostate Cancer |
2024-09-30 |
41% |
| 2016-002854-19 | P2 |
Active, not recruiting |
Prostate Cancer |
2023-02-03 |